advertisement

Topcon

Shirato S 9

Showing records 1 to 9 | Display all abstracts from Shirato S

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Sakata R
Japanese Journal of Ophthalmology 2021; 65: 591-597
94535 The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15
Sakata R
Advances in Therapy 2021; 38: 3760-3770
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Fujishiro T
Japanese Journal of Ophthalmology 2021; 65: 591-597
94535 The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15
Fujishiro T; Saito H
Advances in Therapy 2021; 38: 3760-3770
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Saito H; Nakamura N
Japanese Journal of Ophthalmology 2021; 65: 591-597
94535 The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15
Honjo M; Shirato S
Advances in Therapy 2021; 38: 3760-3770
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Honjo M; Shirato S
Japanese Journal of Ophthalmology 2021; 65: 591-597
94535 The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15
Aihara M
Advances in Therapy 2021; 38: 3760-3770
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Miyamoto E; Yamada Y; Aihara M
Japanese Journal of Ophthalmology 2021; 65: 591-597

Issue 22-2

Change Issue


advertisement

Oculus